

HBM4EU project

science and policy for a healthy future

Calculating European Reference Values (ERVs) and data analysis of HBM data aligned studies in HBM4EU Eva Govarts - VITO 2nd HBM4EU Training School 2018 Aim: data analysis aligned studies at EU level

Needs:

- Harmonized variables → pooled dataset
- Central data analysis
- \rightarrow harmonized codebooks developed by WP10
- \rightarrow research protocols developed by T10.4 partners
- → exposure distributions / European reference values calculated by statistical working group (ANSP, UBA, VITO)

Existing HBM data

- = heterogeneous data
- Different matrices
- Different time periods
- No EU coverage
- Not always access to individual data
- Different study populations
- No analytical quality assurance

HBM data aligned studies

= more homogeneous data

• Same matrix (only check alignment of type of urine sample (morning, spot, 24h), blood sample (fasting/non-fasting, serum/plasma))


HBM4EU data analysis

- Time period 2014-2018
- EU coverage
- Access to individual data
- Selected study populations
- Quality assurance labs

Different strategy depending on homogeneity of the data!!




Different strategy



 Aggregated data calculated with the HBM4EU R-script

• Individual data \rightarrow pooled dataset

STATISTICAL ANALYSES



2nd HBM4EU Training School, Nijmegen, November 19-23, 2018

R-script developed by WP10 data management team harmonized aggregated descriptive statistics

- Whole population + stratified by some parameters (sex, age, educational level, season, smoking status, sampling year)
- Values below LOD/LOQ imputed assuming normal/lognormal distribution
- Descriptive statistics
 - N
 - % below LOD-LOQ
 - Percentiles (P5, P10, P25, P50, P75, P90, P95) and 95% Cl
 - Mean, standard deviation/error, 95% Cl
 - Geometric mean and its 95% Cl

Three steps approach

- Step 1: Inventory of available HBM data collections
- Step 2: Construction of a suitable pooled dataset



• Step 3: Authorization to derive a valid ERV



Inventory of available HBM data collections

 \rightarrow Selection of homogeneous HBM data

- Type of substance / biomarker / matrix
- Type of population
- Age range
- Time period
- Sampling
- Representativeness (national, regional, etc.)
- Quality assurance and comparability analytical methods

Construction of a suitable pooled dataset

- Constitution of one dataset by pooling all data coming from the selected data collections (reference sample)
- Apply splitting criteria to focus on a dataset for which it's relevant (and possible) to derive an ERV
 - Exclusion criteria: exclude participants that are not considered appropriate to be derived an ERV from (e.g. pregnant status)
 - Partitioning criteria: create sub-groups to derive sub-ERVs when relevant (when sub-ERVs are significantly different for sub-groups of the population) (e.g. sex, age)

Authorization to derive a valid ERV

- Sufficient sample size: 120 individuals to calculate 95% CI for the 95th percentile
- Representativeness: is the dataset representative of the population for which the ERV is derived?

If authorization criteria are not met → return to previous step to modify dataset

Once dataset is built:

 \rightarrow percentiles of the reference distribution may be estimated by non-parametric methods

 \rightarrow UBA, ANPS, VITO will work on a R-script to calculate ERVs in a harmonized and uniform way




Within T10.4 research protocols will be developed by expert partners for the statistical analyses at EU level.

For the aligned studies, protocols will focus on:

- Geographical comparisons
- Determinants of exposure
- Time trends (in collaboration with T8.2)

Time trends (in collaboration with task 8.2)



Determinants of exposure:

what if important variables/information is missing for a certain data collection?

 \rightarrow list of mandatory – optional variables

mandatory missing \rightarrow data collection cannot participate optional missing \rightarrow sensitivity analysis without data collection State the research question Background Objective

Methods

- Study Design: Studies needed
- Variables needed
 - Exposure variables (specify which biomarkers)
 - Accompanying variables
 - \rightarrow indication of mandatory and optional variables!
- Statistical analyses
- Substance specific issues

Organization, Time schedule, Publication

Organization-publication

- Each participating data collection will be included in the study protocol working group and is as such informed about the data analyses at EU level
- Each participating data collection is entitled to request to include 2 co-authors in scientific publication of results considering provided data

(see publication policy at <u>https://www.hbm4eu.eu/private/work-package-</u> webpage/scientific-and-administrative-management/ under work package 2)

. . .

Each data collection is free to do data analysis on their own data collection's data, e.g.

- Determinants of exposure at level of the data collection
- Looking into the association with health effects possibly included in the data collection's questionnaires, biomarkers of effect?

Thank you for your attention

If you have any questions about data analysis

Don't hesitate to contact the HBM4EU WP10 statistical working group! VITO: <u>eva.govarts@vito.be</u> ISGlobal: <u>martine.vrijheid@isglobal.org</u>

UBA: nina.vogel@uba.de

ANSP: loic.rambaud@santepubliquefrance.fr



Contacts

Eva Govarts: <u>eva.govarts@vito.be</u> Sylvie Remy: <u>sylvie.remy@vito.be</u> Liese Gilles: <u>liese.gilles@vito.be</u> Greet Schoeters: <u>greet.schoeters@vito.be</u>

Speaker's information

Eva Govarts works as researcher – biostatistician at the Flemish Institute for Technological Research (VITO), Mol, Belgium. She received training in biomedical sciences, applied and biostatistics. In HBM4EU she is task leader of task 10.4 on the data analysis and generation of European reference values (RVs) and together with Greet Schoeters she is co-leading WP10.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733032.